Results 101 to 110 of about 1,869 (168)

Correction: Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin). [PDF]

Dermatol Ther (Heidelb)
Guttman-Yassky E, Irvine AD, Gooderham M, Weidinger S, Spelman L, Silverberg JI, Crane H, ElMaraghy H, DeLuca-Carter L, Piruzeli MLB, Martimianaki G, Pierce E, Agell H, Thaçi D.   +13 more
europepmc   +1 more source

Treatment Outcomes of Lebrikizumab after Switching from Dupilumab in Moderate-to-Severe Atopic Dermatitis involving the Head and Neck Area. [PDF]

Dermatol Ther (Heidelb)
Avallone G, Margiotta FM, Bombelli A, Gargiulo L, Foti C, Trave I, Rossi M, Magnaterra E, Pigliacelli F, Malagoli P, Giacalone S, Portarapillo A, Patruno C, Schettini N, Bonzano L, Pezzolo E, Chello C, Gori N, Brunasso G, Veronese F, Ortoncelli M, Tolino E, Azzolini A, Bellinato F, Hansel K, Di Brizzi EV, Gurioli C, Esposito M, Giuffrida R, Barei F, Calzari P, Burroni AG, Gola M, Mariano M, Fargnoli MC, Napolitano M, Grieco T, Peris K, Savoia P, Ribero S, Girolomoni G, Stingeni L, Balato A, Costanzo A, Marzano AV, Narcisi A, Ferrucci SM.   +46 more
europepmc   +1 more source

Comparative Data on Long-Term Efficacy of Biologics in Moderate-to-Severe AD: An Expert Perspective on Using Indirect Comparison Methodology. [PDF]

Dermatol Ther (Heidelb)
Augustin M, Hong HC, Torres T, Issa NT.
europepmc   +1 more source

Treatment of juvenile bullous pemphigoid with lebrikizumab

JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Marcel Wittenberg, Farzan Solimani, Amrei Dilling, Rawan Snobar, Kamran Ghoreschi, Marisa Klemp, Kerstin Kusch   +6 more
openaire   +2 more sources

Cutaneous lymphomas reported following the use of dupilumab, nemolizumab, tralokinumab, or lebrikizumab: A case investigation based on JADER database and disproportionality analysis. [PDF]

Intractable Rare Dis Res
Tanaka H, Ishii T.
europepmc   +1 more source

Lebrikizumab is Efficacious in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Regardless of Atopic Comorbidities

Background Atopic comorbidities are common in patients with atopic dermatitis (AD) and increase disease burden. Lebrikizumab monotherapy demonstrated efficacy and safety through 52 weeks in patients with moderate-to-severe AD in phase 3 trials (ADvocate1
de Bruin-Weller, Marjolein, Zhong, Jinglin, Bieber, Thomas, Boguniewicz, Mark, Mehta, Vinay, Infection & Immunity, Atwater, Amber Reck, MS Dermatologie/Allergologie, Sher, Ellen R, Golant, Alexandra, Dawson, Zach, Calleja, Lidia Rodriguez, Carrascosa, Jose-Manuel   +12 more
core  

Tralokinumab as a cost-saving treatment option for adults and adolescents with moderate-to-severe atopic dermatitis enrolled in US health insurance plans: a budget impact analysis. [PDF]

J Comp Eff Res
Grindley R, Houde L, Sawad AB, Balu S, Schneider S.   +4 more
europepmc   +1 more source

Letter: Lebrikizumab for Refractory Atopic Dermatitis

Dermatitis®
Natalia V, Chalupczak, Peter, Lio
openaire   +2 more sources

Therapy-associated facial redness in atopic dermatitis: insights from a case series. [PDF]

An Bras Dermatol
Sabas-Ortega K, García-González S, Ara-Martín M, Morales-Moya AL, de la Fuente Meira S, Bularca E, Villagrasa-Boli P, Martinez-Lostao L, Rivera-Fuertes I, Prieto-Torres L.   +9 more
europepmc   +1 more source

Correction: Bridging the Gap in Chronic Prurigo Care: Evidence-Based Diagnostic and Therapeutic Recommendations from a Delphi Consensus Panel. [PDF]

Dermatol Ther (Heidelb)
Mendes-Bastos P, Lobo I, Pires da Rosa G, Pimenta R, Gonçalo M, Delphi panel.   +5 more
europepmc   +1 more source